Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - SECOND SIGHT MEDICAL PRODUCTS INC | s108387_ex99-1.htm |
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 5, 2017
| SECOND SIGHT MEDICAL PRODUCTS, INC. | |||||
| (Exact Name of Registrant as Specified in Its Charter) | |||||
| California | |||||
| (State or Other Jurisdiction of Incorporation) | |||||
| 333-198073 | 02-0692322 | ||||
| (Commission File Number) | (IRS Employer Identification No.) | ||||
12744 San Fernando Road, Suite 400 | |||||
| (Address of Principal Executive Offices) | |||||
| (818) 833-5000 | |||||
| (Registrant’s Telephone Number, Including Area Code) | |||||
| (Former Name or Former Address, if Changed Since Last Report) | |||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On December 5, 2017, Second Sight Medical Products, Inc. (the “Company” or “we”) issued a press release announcing market entry into Iran, implanting the first two patients with the Company’s Argus® II Retinal Prosthesis System (“Argus II”). The implant was facilitated by the country’s exclusive distribution partner for Iran, Arshia Gostar Darman Co. Ltd.
The implants were performed in Shiraz, Iran during November 2017, by Professor Mohsen Farvardin and his team at the Shiraz Pars Hospital and Khalili Hospital, Shiraz Medical Science University in 44-year-old and 33-year-old patients with Retinitis Pigmentosa.
A copy of our press release entitled “Second Sight Announces Market Entry into Iran with First Two Implants of Argus II Retinal Prosthesis System” is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release issued December 5, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 8, 2017
SECOND SIGHT MEDICAL PRODUCTS, INC.
| /s/ Thomas B. Miller | |
| By: Thomas B. Miller | |
| Chief Financial Officer |